- Codexis has entered into an agreement with an innovator pharmaceutical company to manufacture 50 grams of small interfering RNA (siRNA) using its ECO Synthesis platform.
- The material will support preclinical development of a cardiovascular therapeutic candidate and demonstrate the platform’s ability to scale RNA manufacturing beyond research volumes.
Codexis has entered into an agreement with an innovator pharmaceutical company to manufacture 50 grams of small interfering RNA (siRNA) using its proprietary ECO Synthesis manufacturing platform. The material will support preclinical development of a therapeutic candidate targeting a cardiovascular indication.
Under the agreement, Codexis will produce siRNA material for the partner’s preclinical program. The engagement is intended to demonstrate the platform’s capability to deliver RNA quantities beyond early research volumes and could support potential scale-up and manufacturing if the program advances.
ECO Synthesis is Codexis’ proprietary manufacturing technology designed to enable scalable and high-fidelity production of complex siRNA therapeutics. As RNA therapeutics move beyond rare disease applications into broader therapeutic areas, manufacturing requirements are expected to increase. The company stated that its platform is designed to support efficient scale-up while maintaining product consistency.
“We are excited about this relationship as it represents an important entry point into what could become a high-volume opportunity.”
Alison Moore, President and Chief Executive Officer of Codexis
The project is expected to demonstrate the ability of the ECO Synthesis platform to support the production of RNA material at quantities relevant to therapeutic development programs and establish a potential pathway toward larger-scale manufacturing as the partner’s candidate progresses through development.
